Objective. To study the pharmacokinetic behaviour of hypoxoside taken orally by 24 patients with lung cancer.
dose studies. It was due to an active enterohepatic recirculation in some patients and a distinct lag phase in others together with zero-order rate of formation of rooperol in the colon. Computer modelling indicated a single open-compartment model in which the mass of the patient did not influence volume of distribution and clearance because formation of the metabolites is dependent on the metabolising capacity of the patient. However, the elimination of the metabolites follows firstorder kinetics with half-lives ranging from 50 hours for the major metabolite to 20 hours for the two minor metabolites. Multiple-dose studies also showed large interpatient variation.
Conclusion. In order to reach metabolite levels near 100~g/ml, which have been shown to be tumouricidal after enzymatic deconjugation to rooperol, maintenance doses need to be individualised for each patient. For most patients, however, a daily dose of 2 400 mg was sufficient.
S Atr Med J 1995; 85: 861-865.
Hypoxoside is the major diglucoside found in extracts of the corms of several Hypoxis species. ' -4 Historical and anecdotal cases of cancer cure by drinking extracts of Hypoxis led to a recognised claim for its value as an anticancer remedy.
5
In vitro hypoxoside has been shown to be non-toxic to cancer cells at concentrations up to 100~g/mI.6.7 However, when it is hydrolysed to its aglucone, rooperol, by [3-glucosidase, cytotoxicity is found at concentrations ranging from 2 to 10~g/mI.6.7 This action may be related to the formation of reactive semiquinones and quinones which are known to occur with dicatechols such as the closely related cytotoxic agent, nor-dihydroguaiaretic acid."
In vivo hypoxoside has remarkable pharmacokinetic properties. After oral ingestion the parent drug is not found in the circulation. Only phase 11 metabolites (glucuronides and sulphates) of rooperol are found which are also nontoxic in tissue culture experiments!·6 Furthermore, a very distinct species difference is present in so far as the rooperol metabolites are found in the bile only of experimental animals such as the mouse, rat and dog, while they appear in the serum of man and the baboon. 4 ,6 We obtained permission from our Ethics Committee and the South African Medicines Control Council to conduct a phase I pharmacokinetic and toxicity trial with 24 lung cancer patients for whom no alternative therapy was available, based on the arguments that: (I) the pharmacokinetic properties of hypoxoside preclude its use in rodent models for in vivo anticancer studies; (il) several lung cancer cell lines are extremely sensitive to rooperol;6 and (iil) rooperol is not a mutagen in the Ames test (to be published elsewhere). , In this report we document the pharmacokinetic properties of the metabolites when hypoxoside is taken orally by humans.
Material and methods
ophthalmoscopy and audiometry as well as full haematological and biochemical investigations.
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Patient eligibility
Patients had to be above 21 years of age with histologically proven squamous cell, large-cell or adenocarcinoma of the bronchus. Informed consent according to the Declaration of Helsinki was required from each patient. Exclusion criteria included impaired renal, hepatic or cardiac function, concomitant anticancer therapy, inadequate performance status (H2 or lower), and patients who, in the opinion of the investigator, had less than 3 months to live. 
Analyses and pharmacokinetic calculations
Hypoxoside metabolite concentrations were measured by high-performance liquid chromatography (HPLC) according to the method of Kruger et al. 9 For pharmacokinetic calculations a single open-compartment model'o was used initially to fit concentration-time data of the metabolites as they became available. The single-dose data were analysed after completion of the trial by using the digital computer programme NONMEM (version 2, level 1, double precision). 
Medication
Hypoxoside was supplied by Essential Sterolin Products in capsule form, each capsule containing 200 mg of standardised plant extract. Fig. 1 shows a high-performance liquid chromatogram of the contents of a capsule which illustrates the elution profile of hypoxoside as described by Kruger et al. ' Routine HPLC analyses assured uniform quality of each batch of plant extract within the following limits: 50 -55% hypoxoside, 8 -12% f3-sitosterol and 0,2 -0,3% l3-sitosterol glucoside. The remaining 33 -42% of the extract, not detectable by the HPLC system, consisted largely of complex carbohydrates with traces of reducing sugars, amino acids, tannins and flavonoids. Tests for alkaloids were negative. 
Study design
The approved protocol included a randomised, open, singledose study with three dosage levels (8, 12 and 16 capsules) administered to three groups of the 24 patients. The first group of 6 patients who entered the trial also participated in a controlled multiple-dose study for 11 days.
Patients were hospitalised in the Radiation Oncology Ward, Karl Sremer Hospital, Sellville, W. Cape for the singleand multiple-dose studies. Upon admission the medical histories of all patients were recorded and they underwent thorough baseline physical examinations which included full neurological and cardiological examinations, I'olllme 85 No. 9 -September 1995 SAMJ
.. Differences are assumed to be due to random inter-and intrasubject variation. Results are also presented in Table I . In spite of the increased number of parameters the fit of the two-compartment model to the data is significantly worse than the one-compartment model, since the difference in objective function (OBJ) is 7,4. Model 1 is therefore considered appropriate in further model building.
Model 3 in Table I incorporates mass as a function of clearance. The increase in the objective function of 78 indicates that it is not appropriate to express clearance proportional to mass for this metabolite. Model 4 includes mass in volume of distribution which resulted in an increase of 49,4 in the objective function and is therefore not appropriate. minutes is a mixed glucuronide-sulphate conjugate of rooperol. The two minor metabolites A (Rt = 7,6 minutes) and C (Rt = 9,6 minutes) are the diglucuronide and disulphate conjugates, respectively.
The concentration-time relationship of the major metabolite B, studied in groups of 7,7 and 6 patients who received single doses of 1 600, 2 400 and 3 200 mg of standardised plant extract respectively, is shown in Fig. 3 . It is clear that a relatively large interpatient variation exists. This is understood in terms of the fact that the concentration of metabolites in the serum obviously depends both on the rates of deconjugation of hypoxoside and on the conjugation of rooperol. Furthermore, an enterohepa:tic recirculation is evident in some patients where the initial rapid rise in concentration of metabolite B is followed by a drop and a further rise in concentration during the first 15 hours after ingestion. In some patients a distinct lag phase is present before appearance of metabolite B. Calculations of the average area under the curve (AUC) of the concentration-time relationships revealed that it is not linearly related to dose. If the average AUC of the 1 600 mg dose is taken as one, relative values of 0,86 and 1,55 are obtained for the 2 400 and 3 200 mg doses respectively. This implies that formation of rooperol, and possibly its absorption, is a zero order saturable process. Consequently escalating doses usually given in phase I trials in order to reach toxic blood levels were not applicable in this study.
The data shown in Fig. 3 were subjected to NONMEM analyses in a stepwise fashion to fit the following models:
A one-compartment open model (model 1) assuming that all patients have the same clearance (Cl), volume of distribution (V), rate of absorption (ka) and absorption lag time (Tlag). Differences are assumed to be due to random inter-and intrasubject variation. Iterative estimates of the' fixed effects parameters with residual interindividual variance (w) and 'residual intrasubject error variance (a 2 ) are presented in Table I . Table I . Pharmacokinetic parameters of the major metabolite (8 in Fig. 2 ) of hypoxoside obtained from NONMEM analyses of singledose data (see Fig. 3 Fig. 4 (lower part) is the variation in concentrations of metabolite B in 6 patients who received 2 400 mg of hypoxoside daily divided into three equal doses. The therapy was interrupted on day 9 (216 hours) which resulted in the decline in concentration of metabolite B as shown in Fig. 4 .
Discussion
When the pharmacodynamic and pharmacokineticp roperties ofhypoxoside were investigated by us 4 ·ifit became clear that its possible application as a pro'drug in cancer therapy needed to be investigated further. Pj!rt of the phase I study undertaken was to assess the ; pharmacokinetic behaviour of the phase 11 metabolites since no hypoxoside or rooperol appear in the blood. Only the phase II metabolites can be measured, of which the mixed glucuronide-sulphate is the major component. The diglucuronide and disulphate metaboJites appear in the blood at steady state as minor.metabolites (approximately 20% of the major metabolite) because their half-lives are only 20 hours in comparison with the 50 hours of the major metabolite.
It was possible to fit the concentration-time relationship of the major metabolite to the simplest model, i.e. a single open-compartment model which provided reasonable estimates of the different pharmacokinetic parameters (Table I , model 1). It must be kept in mind that for calculation of clearance and volume of distribution a bio-availability factor is needed which can only be determined after intravenous administration of the compounds in question. The finding that there is no relationship between clearance, volume of distribution and mass of the patient (Table I , models 3 and 4), however, justifies the indirect method of analysing the data. It is also understandable that mass should not play a significant role since the extent of conversion of hypoxoside to rooperol, and in. turn, rooperol to phase 11 metabolites, is obviously more dependent on the metabolising activity of the gastro-intestinal system (particularly the colon) an9 the liver of the patient rather than the mass of the patient. The rather large interpatient variation observed both with single':dose and multiple-dose therapy (Figs 3 and 4) is probably also allied to the metabolising capacity of the patient. This includes a lag phase for appearance of the metabolites in the blood which has a coefficient of variation of 225% (Table I) . Some patients also clearly showed active enterohepatic recirculation of the metabolites shortly after hypoxoside was ingested (Fig. 3) .
Because of the relatively large interpatient variation, and the zero-order formation of metabolites but predictable firstorder elimination kinetics, the long-term maintenance doses of patients were adjusted in the toxicity study when necessary during hospital visits according to their combined • Not included. Volllme 85 No.9 September 1995 SAMJ metabolite serum concentrations in order to maintain a steady-state concentration near 100~g/ml. Based on in vitro experiments' the latter was considered adequate for formation of tumouricidal rooperol concentrations. For most patients a daily dose of 2 400 mg (4 capsules 3 times a day) was sufficient.
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